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Endocardial cushionsIn fetal valve maturation the mechanisms by which the relatively homogeneous proteoglycan-rich
extracellular matrix (ECM) of endocardial cushions is replaced by a specialized and stratiﬁed ECM found in
mature valves are not understood. Therefore, we reasoned that uncovering proteases critical for ‘remodeling’
the proteoglycan rich (extracellular matrix) ECMmay elucidate novel mechanisms of valve development. We
have determined that mice deﬁcient in ADAMTS5, (A Disintegrin-like And Metalloprotease domain with
ThromboSpondin-type 1 motifs) which we demonstrated is expressed predominantly by valvular
endocardium during cardiac valve maturation, exhibited enlarged valves. ADAMTS5 deﬁcient valves
displayed a reduction in cleavage of its substrate versican, a critical cardiac proteoglycan. In vivo reduction
of versican, in Adamts5−/− mice, achieved through Vcan heterozygosity, substantially rescued the valve
anomalies. An increase in BMP2 immunolocalization, Sox9 expression and mesenchymal cell proliferation
were observed in Adamts5−/− valve mesenchyme and correlated with expansion of the spongiosa
(proteoglycan-rich) region in Adamts5−/− valve cusps. Furthermore, these data suggest that ECM remodeling
via ADAMTS5 is required for endocardial to mesenchymal signaling in late fetal valve development. Although
adult Adamts5−/− mice are viable they do not recover from developmental valve anomalies and have
myxomatous cardiac valves with 100% penetrance. Since the accumulation of proteoglycans is a hallmark of
myxomatous valve disease, based on these data we hypothesize that a lack of versican cleavage during fetal
valve development may be a potential etiology of adult myxomatous valve disease.Disintegrin-like and Metallo-
T, epithelial to mesenchymal
A, smooth muscle alpha-actin;
al; SLV, semilunar valves; PA,
e; MV, mitral valve.
ive Medicine and Cell Biology,
a, Charleston, SC 29425, USA.
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Adult cardiac valve disease is a public health problem of growing
concern affecting up to 5% of individuals, with 25% of the aged
population eventually developing aortic valve sclerosis, a diagnostic
indicator of valve disease (Hinton and Yutzey, 2011; Hoffman and
Kaplan, 2002). The fact that most diseased valves have an underlying
malformation (Roberts et al., 2005) suggests the possibility that adult
disease could originate, at least in part, through subtle, subclinical
anomalies of valve development. A hallmark of cardiac valve
developmental anomalies and adult disease is accumulation of
proteoglycans and loss of extracellular matrix (ECM) stratiﬁcation
(Gupta et al., 2009a; Hinton et al., 2006; Weismann and Gelb, 2007).
In early valve development the ECM is proteoglycan-rich but during
valve maturation this provisional EDM is replaced by stratiﬁed ECM,which includes collagen and elastin. This specialized, ECM is required
to effectively regulate unidirectional blood ﬂow in the rapidly
growing fetus and in the adult (Combs and Yutzey, 2009; Hinton et
al., 2006). The process by which the initial ECM is remodeled during
valve maturation remains poorly understood since gene deletions in
mice often result in embryonic death or a subclinical or incompletely
penetrant valve phenotype. These studies address the overarching
hypothesis that proteoglycan accumulation in myxomatous valves
results from reduced ECM cleavage and directly contributes to
anomalous valve maturation or homeostasis and is not simply a
secondary manifestation of disease.
Initially endocardial cushions, the precursors to adult valves, are
rather large and block shaped with a proteoglycan-rich ECM (Cooley
et al., 2008; Kern et al., 2007;Wirrig et al., 2007). This provisional ECM
is required for the epithelial to mesenchymal transformation (EMT)
(Runyan and Markwald, 1983) that contributes to the cellularization
of the cushions and migration of extra-cardiac cells (Hutson and
Kirby, 2003). The endocardial cushion ECM also permits the
proliferation of mesenchyme during early stages of valve develop-
ment (Hinton et al., 2006; Lincoln et al., 2004; Rabkin-Aikawa et al.,
2005). Versican is a large aggregating proteoglycan of ECM (Cooley et
al., 2008; Henderson and Copp, 1998; Ito et al., 1995; Kern et al., 2006,
2007; Yamamura et al., 1997; Zako et al., 1995) that is abundant
153L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164during the formation of endocardial cushions, and is essential for their
formation, but is dramatically reduced with restricted expression in
mature valves. There are 4 splice variants of versican, each containing an
N-terminal domain that binds hyaluronan and a C terminal domain that
interacts with other ECM molecules (Margolis and Margolis, 1994)-
(Aspberg et al., 1997, 1999; Wu et al., 2005). The variants differ in the
presence/absence of internal glycosaminoglycan (GAGα or GAGβ)
domains that are susceptible to cleavage by a subset of ADAMTS
proteases referred to as proteoglycanases (ADAMTS1,4,5,9,20).
ADAMTS5 cleavage of aggrecan contributes to the progression of
osteoarthritis disease (Bondeson et al., 2008; Huang and Wu, 2010;
Yatabe et al., 2009) and recent work demonstrated its requirement for
versican turnover during limb morphogenesis (Enomoto et al., 2010;
Longpre et al., 2009; McCulloch et al., 2009b).
Our previous studies established that versican is cleaved during
cardiac development and that versican cleavage fragments are
localized subjacent to the endocardium of maturing valves (Kern et
al., 2006). Examination of mice heterozygous for a LacZ insertion in
Adamts9 revealed a constellation of adult cardiovascular phenotypes
including enlarged adult cardiac valves with increased proteoglycans.
However, the early embryonic death of the Adamts9 null mice
precluded analysis of its role in valve development (Kern et al.,
2010). Here, we tested the speciﬁc hypothesis that the endocardial
expression of ADAMTS5 in developing cardiac valves was essential for
versican cleavage during the fetal sculpting phase of valve develop-
ment (Longpre et al., 2009; McCulloch et al., 2009b). The experimen-
tal ﬁndings validated the hypothesis and revealed a novel role for
ADAMTS5 in differentiation of valvular mesenchyme and stratiﬁca-
tion of ECM. Since an increase in proteoglycans, including versican, is
associated with myxomatous valve disease (Kenagy et al., 2009; Kern
et al. 2010; Seidelmann et al., 2008; Theocharis, 2008), the data
suggest further investigation of altered ADAMTS5 gene expression and
versican proteolysis as contributing factors in congenital valve
malformations and adult valve disease.
Methods
Gene-targeted mice
All mouse experiments were done under protocols approved by
the Cleveland Clinic Foundation's Institutional Animal Care and Use
Committee (IACUC) and the Medical University of South Carolina
IACUC. The Adamts5−/− mice used in this study were the
Adamts5tm1Dgen/J gene-targeted allele available from Jackson labora-
tories (Bar Harbor, ME), and were bred into C57Bl/6 (N10 generations)
andmaintained as previously described (Jungers et al., 2005;McCulloch
et al., 2009b). The Vcanhdf lacZ insertion allele was provided by Roche™
(Mjaatvedt et al., 1998) and also maintained on a pure C57Bl/6
background. Genotyping of Adamts5 mice was by PCR as previously
published (McCulloch et al., 2009b). β-gal staining was done as
previously described (Jungers et al., 2005; McCulloch et al., 2009b). To
mark cardiac neural crest cells, double transgenic Wnt1-Cre (C57Bl/6)
mice, provided by Dr. Andrew McMahon, Harvard University, Cam-
bridge, Mass and TgR(ROSA26)26SOR mice were used as described
previously (Danielian et al., 1998; Soriano, 1999). Adamts5 expression
was evaluated by β-gal staining of Adamts5tm1Dgen/J mice generated by
an inactivating insertion of a dicistronic IRES-lacZ-Pgk-Neomycin
cassette into exon 2 (McCulloch et al., 2009a).
Antibodies
ADAMTS5 immunolocalization was determined using an
ADAMTS5 polyclonal antibody (Abcam, Cambridge, MA). Rabbit
polyclonal antibodies against the GAGβ domain of versican were
generated by S. Hoffman (Medical University of South Carolina) (Kern
et al., 2007). Rabbit polyclonal antibodies against the C-terminalsequence of the neo-epitope of versican V0/V1 generated by
proteolytic cleavage (anti-DPEAAE) (Sandy et al., 2001) were
purchased from Afﬁnity BioReagents (Golden, CO). Mouse monoclo-
nal anti-α sarcomeric actin and anti-α-smooth muscle actin were
obtained from Sigma Chemical Co. (St. Louis, MO). Rabbit polyclonal
antibodies against BMP2 were purchased from Abcam (Cambridge,
MA). Anti-Sox9 was purchased from Santa Cruz (Santa Cruz,
California). PhosphoHistone H3 was purchased from Cell Signaling,
(Carlsbad, CA). Biglycan antibody (LF-159) was a generous gift from
Dr. L. Fisher at the National Institute of Health. Fluor-conjugated
secondary antibodies were purchased from Jackson ImmunoResearch
(West Grove, PA).
Histology and immunohistochemistry
Standard histological procedures were used (Kern et al., 2007); for
the ADAMTS5, GAGβ, Sox9 and DPEAAE staining, E17.5 hearts were
ﬁxed in 4% paraformaldehyde. For ADAMTS5 expression proteinase K
digestion was required with post-ﬁxation of antigen-antibody
complex to inhibit diffusion of ﬂuorescent signal. Amsterdam ﬁxed
tissue (35% methanol; 35% acetone; 5% acetic acid; 25% water) was
used for DPEAAE staining at E15.5 and BMP2. Note the Amsterdam
ﬁxative for DPEAAE revealed increased amount of staining relative to
paraformaldehyde ﬁxed tissues at these fetal time points. Modiﬁed
Movat staining was performed as previously described (Kern et al.).
An Olympus BX40 microscope was used for bright-ﬁeld microscopy
and the DP2-BSW (v1.4, build 2743) software (Olympus Corporation,
Center Valley, PA) was used for valve cusp and leaﬂet measurements.
For E17.5 Wnt-1Cre-lacZ CNC ‘marked’ sections with overlay
immunolocalization, the transmission mode was used on the Leica
SP2/SP5 (Bannockburn, IL) confocal microscope to detect β-gal
stained cells. In the same image, emission of the ﬂuorescent-
conjugated secondary antibody was detected by sequential scan.
Using Adobe Photoshop™ software, the image from the transmission
mode showing β-gal stained cells was inverted and placed in the blue
channel to visualize CNC ‘lineage-marked’ cells with αSMA, cleaved
versican DPEAAE and ADAMTS5 immunostaining.
Quantiﬁcation of immunoﬂuorescence and Valve Anomalies
Three-dimensional reconstructions: Amira™ 5.3.3 (Visage Imaging,
Andover, MA) was used to generate reconstructions. 100–140 5 μm-
thick parafﬁn sections were used to generate each E17.5 construction.
Volumetric measurements were derived from an average of three
reconstructions eachofAdamts5−/− andWTvalves.Data fromcrosses of
Adamts5−/−mice and Vcanhdf/+were derived from eleven independent
internally controlled litters dissected at E17.5. Volumes for valve
reconstructions are the average of 3 independent reconstructions each
for the Adamts5+/+;Vcan+/+ and Adamts5−/−;Vcan+/+ and 2 from
independent litters for Adamts5−/−Vcan+/hdf.
Quantiﬁcation of valve thickness (not 3d): The widest portion of the
cusps or leaﬂets of valves were used over a minimum depth of 50 μm
using an Olympus BX40 microscope with DP2-BSW (v1.4, build 2743)
software. Three independent measurements were taken per cusp, of
four different sections. The values were averaged. A minimum number
of N=4 animals were used per genotype for statistical analysis.
Quantiﬁcation of IHC data: To quantify expression from immunohis-
tochemical data, digital images of Adamts5−/− and WT heart sections
were acquired at identical confocal settings using the Leica TCS SP5AOBS
Confocal Microscope System (Leica Microsystems Inc., Exton, PA). Using
Amira™ software the positive pixels were measured and normalized to
total tissue area. A minimum of three separate experiments with three
different litters of matched Adamts5−/− and WT were used in the
analysis. To quantify the pixel intensity of pHH3 and Sox9, the total
number of positive nuclear pixels above a background threshold was
counted and normalized to total number of mesenchymal nuclei in the
154 L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164image. For BMP2 quantiﬁcation the total positive pixel area of BMP2
positive pixels over background threshold was quantiﬁed to the total
pixels per cusp area (minus hinge region) of the PA valve and graphed.
Quantiﬁcation of nuclei: The total nuclei in the valve cusps were
counted in sections spanning a depth of at least 50 μmand the number
of nuclei/valve area μm2 was determined using Amira™ in 6
Adamts5−/− hearts and 4 WT hearts.
Statistical signiﬁcance was determined using the Student t-test (2
tailed, type 2), with signiﬁcance (Pb0.05). Statistical data are
presented as the mean±one standard deviation (SD) from the mean.
Results
Adamts5 is expressed in the endocardium and a subset of mesenchymal
cells of maturing and adult murine cardiac valves
Adamts5 expressionwas evaluated by β-gal staining of Adamts5−/−
mice generated by an inactivating insertion of a dicistronic IRES-lacZ-
Pgk-Neomycin cassette into exon 2. The β-gal staining wasFig. 1. Adamts5 is expressed during cardiac valve maturation in regions where versican cle
Adamts5 RNA expression, using mice homozygous for the lacZ insertion in Adamts5 (B, F–H, K
of cleaved versican using an anti-DPEAAE441 neo-epitope antibody (J, O). ADAMTS5 was str
(A, open arrow). β-galactosidase staining of Adamts5 expression was ﬁrst detected in d
immunolocalization until E13.5 (E, solid arrow). ADAMTS5 immunolocalization wasmost int
intense but evident in themyocardium surrounding the developing AV (D, open arrow). At E1
arrow) and in mesenchymal cells of the hinge region (G, H; asterisk). β-gal staining was ev
ADAMTS5 was observed at E15.5 subjacent to the endocardial endothelium (I, solid arrow),
ventricular trabeculae (I, arrowhead). By E17.5 β-gal staining was present in the endocar
ADAMTS5 was immunolocalized at E17.5 subjacent to the endocardium (N, arrow). The N-te
at E15.5 (J, solid arrow) and in the PA wall (J, open arrow). At E17.5 the cleaved versican DP
hinge region (O, asterisk). In adult murine cardiac valves β-galactosidase staining is evident
valves (Q, S) revealed expression throughout the cusps as well as in the annulus (S). PA-pulm
Green (A, C–E, I, N, Q, S)-ADAMTS5; green (J, O)-anti-DPEAAE cleaved versican; red (A, I, J, N, O
neural crest (Wnt-1Cre: Rosa-LacZ “marked” cardiac neural crest (CNC); blue (C, D, J)
F, K=150 μm; C, I, J=200 μm.*-DPEEAE expression is more readily detected in Amsterdashown previously to overlap with the in situ localization of Adamts5
RNA (McCulloch et al., 2009a). ADAMTS5 was detected in the
myocardium underlying the OFT cushions at E11.5 (Fig. 1A, open
arrow). β-gal indicative of Adamts5 RNA expression was ﬁrst detected
in endocardial cushions of the OFT in a subset of embryos at E12.5 in
the endocardium (Fig. 1B, arrow). Immunolocalization of ADAMTS5 in
developing valves was ﬁrst detected at E13.5 in the ECM substratum of
the endocardium (Fig. 1E, arrow) and strong expression was also
observed in the underlying myocardium (Fig. 1E, open arrow). The
detection of ADAMTS5 using the anti-ADAMTS5 antibody required
protease K digestion as well as post-ﬁxation of the ADAMTS5-
antibody complex to improve our threshold of detection. At E14.5,
ADAMTS5 was detected in the ECM and associated with the
endocardium (Figs. 1F-H, solid arrows) of the PV and AV cusps as
well as the developing arterial wall (Figs. 1F, I (E15.5) open arrow).
There was also expression of ADAMTS5 associated with the
endocardium of the developing ventricles (Fig. 1I, arrowhead).
Using a neoepitope antibody that recognizes the ADAMTS cleavage
site in versican (Glu 441-Ala442, V1 sequence enumeration) but notavage fragments are detected. The images show β-galactosidase staining indicative of
–M, P, R, T), immunolocalization of ADAMTS5 (A, C–E, I, N, Q, S), and immunodetection
ongly expressed in the myocardium surrounding the developing OFT cushions at E11.5
eveloping valves at E12.5 in the endocardium (B, solid arrow) but not detected by
ense surrounding developing PV cushions at E12.5 and E13.5 (C, E open arrows) and less
4.5 β-galactosidase staining was found in the endocardium of the PV and AV (F–H, solid
ident in the walls of the great arteries at E14.5 (F, open arrow). Immunolocalization of
in the wall of the aortic artery (I, open arrow) and subjacent to endocardial lining of the
dium (K-M, arrow) as well as in the hinge region of the maturing cusps (L, asterisk).
rminal cleavage fragment of versican, DPEAAE, was found subjacent to the endocardium
EEAE fragment was localized subjacent to the endocardium (O, solid arrow), and in the
in the PV (P), the AV (R) and MV (T). Immunolocalization of ADAMTS5 in adult cardiac
onary artery; Ao-aorta; VS-valvulosinus; MV-mitral valve; OFT-outﬂow tract; A-annulus.
)-αsmoothmuscle actin (αSMA); red (C-E, Q S) propidium iodide blue (A, I, N, O)-Cardiac
αsmooth muscle actin. Scale bars: (A, B, D, E, H, L, N-T)=50 μm; G, M =100 μm;
m ﬁxative compared to paraformaldehyde (see methods section).
Fig. 2. Adamts5 null mice have enlarged and malformed pulmonary valves. H & E
stained frontal sections of the PV fromWT (A, E) and Adamts5−/− (B, F) hearts at E14.5
(A, B) and E17.5 (E, F) same magniﬁcation are shown. Three-dimensional re-
constructions of WT (C, G) and Adamts5−/− mice (D, H) were generated from
histological sections of E14.5 and E17.5 PV. Lt- left cusp of the PV (blue); Rt- right cusp
of the PV (white); An-anterior cusp of the PV (green); D-dorsal; V-ventral; Scale bars:
A=50 μm; C=75 μm; E =150 μm; G=200 μm. Corresponding quantitative data from
reconstructions are listed in Supplemental Table 1.
155L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164intact versican (Sandy et al., 2001), we detected versican fragments
in developing valve cusps, the arterial wall and subjacent to the
ventricular endocardium at E15.5 (Fig. 1J), all regions where
ADAMTS5 was also expressed at this stage. At E17.5, Adamts5 was
detected using LacZ expression in the valvular endocardium
(Figs. 1K–M) and most readily detected on the ventricular aspect
of the OFT valve cusps (Figs. 1K–M). Mesenchymal cells of the
semilunar valves also expressed Adamts5 in the hinge region of the
maturing cusps at E14.5–17.5 (Figs. 1G,L asterisks). Cleaved versican
(anti-DPEAAE immunoreactivity) was colocalized with ADAMTS5
expression in maturing SLV cusps, and was most prominent in the
subendocardial regions at E17.5 (Fig. 1O). Expression of Adamts5
was maintained in the adult murine cardiac valves as detected by β-gal
staining (Figs. 1P,R,T) and immunolocalization (Figs. 1Q,S). The detection
of ADAMTS5 in valvular mesenchyme and differentiated VIC gradually
increased from E15.5 to adult in valve cusps. In the adult ADAMTS5 is
localized within VIC and ECM of the distal cusp and the annulus (Fig. S,
‘A’). These expression patterns suggested that ADAMTS5 and/or
proteolytically cleaved versican had potential roles in valve maturation
and homeostasis. It is important to note that ADAMTS5 is a secreted
protein and is active extracellularly. Although it is initially expressed by
theendocardium, it is associatedwith the ECMofmesenchyme subjacent
to the endocardium. Therefore we do not expect protein expression and
beta-gal as well as the DPEAAE cleaved versican fragments to always
overlap. In addition other ECM proteases including ADAMTS1 {Kern,
2006 #2489} and ADAMTS9 {Kern, 2010 #6621} are present in the
cushions and likely produce DPEAAE versican cleavage fragments in the
developing valve cusps. Since the ADAMTS5 protein is very difﬁcult to
detect by IHC, (it requires protease digestion of the tissue and post-
ﬁxation of the ADAMTS5-antibody complex) the enzymatic beta gal
reaction facilitated detection of gene expression prior to our ability to
detect theprotein at E12.5 andwas used to readily and clearly detect cells
that express ADAMTS5 during valve maturation. We acknowledge that
theremight be differential stability of transcripts and proteins expressed
between thewild type ADAMTS5 allele and the LacZ inserted allele, with
LacZ products likely more stable. However, this would only impact
interpretation of the shutting down of gene expression and not the
initiation of expression at E12.5 which we have demonstrated. The
presence of DPEAAE fragments supports this E12.5 expression of
ADAMTS5, although there is still potential of other ADAMTS molecules
cleaving versican at this early timepoint.
ADAMTS5 deﬁciency results in myxomatous cardiac valves with the most
dramatic anomalies in the pulmonary valve cusps
Previous investigators had reported that adult mice containing an in-
framedeletion of the region encoding the catalytic domain ofAdamts5−/−
were externally normal and that analysis of internal organs did not
reveal any abnormalities (Rogerson et al., 2008). In fact our analysis of
E17.5 hearts revealed no obvious cardiac abnormalities at E17.5.
(Supplemental Fig. 2 A, B). Upon more detailed examination we
discovered that the pulmonary valve cuspswere grossly enlarged in late
fetal development and in the adult. At E14.5 subtle differences in the
hinge region and valve outline (Figs. 2A,B) were evident in Adamts5−/−
mice. Three-dimensional (3D) reconstructions revealed increased
volumes and highlighted these changes in valve shape (Figs. 2C,D;
Supplemental Table 1). During fetal development the severity of the
abnormalities increased and by E17.5 the PV of Adamts5−/− mice was
grossly enlargedandmalformed (Figs. 2E,F). 3D reconstructions of E17.5
PV cusps showed an average of 2.4 fold increase in Adamts5−/− cusp
volume compared to WT littermates (Figs. 2G,H). Reconstructions
highlighted the “balloon shaped” PV at E17.5 in the Adamts5−/− mice,
which resembled the endocardial cushions earlier in development
(E14.5) and prior to maturation (Figs. 2 A–D). The penetrance of the PV
phenotype in Adamts5−/− mice was 100% (n=53; Adamts5−/− and
n=56 WT littermates). Although not as dramatic as the PV, the aorticvalve (AV) cusps were also larger in the Adamts5−/−with an average of
1.5 fold greater volume at E17.5. (Supplemental Table 1; Supplemental
Fig. 2). The mitral leaﬂets at E17.5 also showed a statistically signiﬁcant
increase in leaﬂet thickness in the Adamts5−/− mice compared to WT
littermates (Supplemental Fig. 2). Adult Adamts5−/− mice are viable
with a normal lifespanhowever examination of the PV, AV andMV from
6 month old Adamts5−/−mice revealed signiﬁcantly larger, myxoma-
tous PV (*Pb0.02), AV (*Pb0.04) and MV (*Pb0.04) compared to WT
(Fig. 3) (n=9; Adamts5−/−; n=6; WT). Therefore the Adamts5−/−
mice did not recover from the developmental valve anomalies.
ADAMTS5 expression was maintained in the endocardium and VIC in
all adult cardiac valves in regions associated with ﬁbrous ECM layers
(Fig. 1), notably the hinge region and subjacent to the endocardium.
Increased intercellular space and increased mesenchymal cell number
contributed to the enlarged cardiac valves in ADAMTS5 deﬁcient mice
In our previous work, we determined that the subendocardial
mesenchyme subjacent to the endocardium is condensed concomi-
tant with detection of the versican cleaved fragments (Kern et al.,
2006). High magniﬁcation of histological sections from developing
PVs from Adamts5−/− mice beginning at E12.5, when ADAMTS5 was
Fig. 3. Adult Adamts5−/−mice have myxomatous pulmonary, aortic and mitral valves. Movat pentachrome stained sections of adult WT (A, D, G) and Adamts5−/− valves (D, E, H).
Increased blue staining in the cusps and leaﬂets of Adamts5−/− is indicative of proteoglycans (B, E, H), veriﬁed as versican by IHC (not shown). Quantiﬁcation of the thickness of the
Adamts5−/− versus WT adult PV (A, B), AV (D, E), and MV (G, H) valves are shown in C (*Pb0.02), F (*Pb0.04), and I (*Pb0.04) respectively. PV—n=6 Adamts5−/−; n=6, WT; AV—
n=6 Adamts5−/−; n=3 WT; MV—n=5 Adamts5−/−; n=4 WT. PA-pulmonary artery; Ao-aorta; MV-mitral valve. Black/green bars in (A, B, D, E, G, H) indicate regions of
proteoglycan staining in the free edge where measurements were taken. Scale bars: A, B, D, E, G, H=200 μm.
156 L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164initially detected (Fig. 1B) revealed a decrease in compaction of
subendocardial mesenchyme Figs. 4A, B (blue/red bars). At E14.5
there is an increase in subendocardial mesenchyme accumulation and
compaction in the WT (Fig. 4C, blue bar) not evident in the cusp from
Adamts5−/− mice (Fig. 4D, red bar). By E17.5 there was a dramatic
increase in intercellular mesenchymal space throughout the
Adamts5−/− cusps compared to WT (*Pb0.0001). These data were
quantiﬁed in Fig. 4G, and reported as cell density. There were also
signiﬁcantly more mesenchymal cells within the cusps of Adamts5−/−
deﬁcient hearts (Fig. 4H, *Pb0.03). We further investigated whether
an increase in cell proliferation or reduced apoptosis contributed to
the increased mesenchymal cell number in PV cusps in Adamts5−/−
mice. Using a TUNEL assay at E14.5 and E17.5 there was minimal
apoptosis in valvular mesenchyme and no difference between
Adamts5−/− and WT littermates (data not shown). Using phospho-
Histone H3 (pHH3) as a marker of cell proliferation, we identiﬁed a
statistically signiﬁcant increase in proliferating mesenchymal cells in
the maturing PV cusps of Adamts5−/− mice at both E14.5 and E17.5
(Fig. 5, *Pb0.01, *Pb0.03, respectively); however at postnatal day
8 endocardial and mesenchymal PV cell proliferation did not differ
signiﬁcantly from WT littermates (Figs. 5F,G). These ﬁndings
implicated that both increased extracellular matrix accumulation
resulting in increased mesenchymal space as well as increased
mesenchymal cell proliferation contributed to the grossly enlarged
PV in Adamts5−/− mice by E17.5.
The ADAMTS5 substrate versican accumulates in Adamts5−/− cardiac
valves concomitant with a reduction of versican cleavage fragments
We hypothesized that the accumulation of ADAMTS5 substrates
would be the primary and initial cause underlying the myxomatous
valve phenotype in theAdamts5−/− valves. In addition this hypothesis is
consistent with the observation of increased intercellular space in
Adamts5−/− valve cusps. Therefore we analyzed whether processing of
the ADAMTS5 substrate versican (Longpre et al., 2009; McCulloch et al.,
2009b) was altered in the enlarged valves of Adamts5−/− micebeginning at E12.5 at the onset of detection of ADAMTS5 expression.
Intact versicanwas detected (using anti-GAGβ, versican antibody (Kern
et al., 2007)) prominently in the endocardial cushions ofWT PV cusps at
E12.5. However, compacted subendocardialmesenchymal cells at E12.5
show a loss of versican staining (Fig. 6A, bar). In Adamts5−/− valves
there is a loss of compaction at E12.5 (Fig. 6B, bar) and increased
versican. We initially detected Adamts5−/− expression in the endocar-
dium of developing cushions at E12.5. At this time point in WT valve
cusps detection of the versican cleaved fragment DPEAAE was evident
(Fig. 6C) but not in theAdamts5−/− cusps (Fig. 6D). ByE14.5 the increase
in intact versican and reduction in subendocardial compacted mesen-
chymeweremore prominent. A statistically signiﬁcant increase in intact
versican (using anti-GAGβ, versican antibody (Kern et al., 2007))
(Figs. 6E,F,I,J; *Pb0.003, O) concomitant with marked decrease in anti–
DPEAAE immunostaining (versican N-terminal ADAMTS cleavage
fragment (Sandy et al., 2001)) (Figs. 6G,H,K,L *Pb0.03, P) was observed
in Adamts5−/− mice compared to WT littermates in E14.5, E17.5. At
postnatal day 1 (P1), increased Alcian blue staining was evident in the
Movat pentachrome stained sections of PV from Adamts5−/− mice
(Figs. 6M,N blue) and is associated with versican accumulation
(Figs. 6Q,R). In adult valves an increase in versican was also observed
in the myxomatous valves of ADAMTS5 deﬁcient mice (Figs. 6S,T) and
a reduction of cleaved DPEAAE immunodetection (Figs. 6U,V). These
data suggested that loss of ADAMTS5 resulted in decreased proteolytic
processingof versicanduring semilunar valvematuration, accumulation
of uncleaved versican, and contributed to in the myxomatous valve
phenotype in Adamts5 deﬁcient mice. We conclude that the dramatic
increase in versican accumulation also contributes to the increase in the
spongiosa or proteoglycan-containing layer in the valves of Adamts5−/−
mice compared to WT.
The other aggregating proteoglycan substrate of ADAMTS5,
aggrecan, has not been detected in mammalian cardiac valves
(Angel et al., 2011) and data not shown. However, biglycan, a small
leucine rich proteoglycan (SLRP) has been reported as an in vitro
substrate of ADAMTS5 (Melching et al., 2006), and its accumulation
has been associated with human valve disease (Derbali et al., 2010;
Fig. 4. An increase in mesenchymal cell number with increased intercellular space
contributes to the enlarged valve cusps in Adamts5−/− mice. H & E stained sections of
maturingPVcusps of E12.5, E14.5 andE17.5WT (A, C, E) andAdamts5−/− (B,D, F) embryos
are shown. Blue bars in A, C, and E represent the normal progression of subendocardial
mesenchymecompactionevident inWTembryocuspsbut absent in theAdamts5−/− cusps
(highlighted by the red bars shown in panels B, D, and F). In panel G the number of total
cells (E17.5) per relative cusp area in μm2 is represented by the mean±SD; * denotes
Pb0.0001. Total nuclei were counted in the semi-lunar cusps from WT and Adamts5 null
embryos at E17.5 spanning a 40 μmdepth. Themean of the total nuclei/cusp is graphed in
H; error bars represent +/− SD of the mean; * denotes Pb0.03. Scale bar: A=30 μm.
Fig. 5. Mesenchymal cell proliferation is increased in pulmonary valve cusps from
Adamts5−/− mice at E14.5 and E17.5. Proliferation of SLV leaﬂets using anti-
phosphoHistoneH3 (pHH3-green) in WT (A, C, F) and ADAMTS5 null (B, D, G) embryos
was evaluated in frontal sections. Mesenchymal cells positive for pHH3 (arrows) and
endothelial cells (arrowheads) are shown in developing SLV leaﬂets (demarcated in C
by dashed lines) (A, B, E14.5; C, D, E17.5; F, G, P8). Solid arrows and arrowheads denote
examples of strong staining of nuclei in mesenchymal and endocardial cells
respectively. The open arrow shows an example of punctate staining of mesenchymal
nuclei. Red - propidium iodide (PI) staining of nuclei. Panel E shows mean±SD of the
percent positive mesenchymal pHH3 nuclei from Adamts5−/− and WT from E14.5
(* denotes Pb0.01) and E17.5 (* denotes Pb0.03); n=6 Adamts5−/− and n=6 WT.
pHH3 at P8was not signiﬁcantly different between Adamts5−/− andWT. SLV-semilunar
valve; P8-postnatal day 8. Scale bars: A=25 μm, C,F=50 μm.
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contributed to the myxomatous valve phenotype in Adamts5−/−mice
in late fetal development and/or in the adult (Supplemental Fig. 1).
Biglycan was detected in the PV of both Adamts5−/− and WT at E17.5
notably in the attachment point of the PV cusps (Supplemental Fig.
1A, B, arrow). However there was not an accumulation of biglycan at
E17.5 (Supplemental Fig. 1A–D) in the Adamts5−/− PV. In the adult
Adamts5−/− mice biglycan was misexpressed in the PV, although the
extent of expression was not increased compared to WT littermates
(Supplemental Figs. 1 G–J) when normalized to valve area. This is in
contrast to the ADAMTS5 substrate versican that showed dramatic
accumulation by E17.5 and in the adult (Fig. 6).BMP2 localization and Sox9 expression are not down-regulated in
Adamts5−/− valve cusps compared to WT littermates
It is well established that the TGFβ superfamily is involved in valve
formation, maturation and disease by mediating changes in the ECM
(Carta et al., 2006, 2009; Combs and Yutzey, 2009; Galvin et al., 2000;Jian et al., 2003; Kim et al., 2008; Ng et al., 2004; Snarr et al., 2008).We
examined expression and localization of BMP2 during fetal valve
maturation. Using digital images from confocal microscopy, the
percent positive pixel area of BMP2 immunolocalization in the PV
cusps from Adamts5 deﬁcient micewas compared toWT littermates at
E15.5, E17.5 and P1. At E15.5 BMP2 is localized throughout the
developing cusps in the WT and Adamts5−/− PV (Figs. 7A,B). We
Fig. 6. Versican processing is decreased in semilunar valves from ADAMTS5 deﬁcient mice and contributes to their myxomatous phenotype. Histological sections of PV cusps from
WT (A, C, E, G, I, K, M, Q, S, U) and Adamts5−/− (B, D, F, H, J, L, N, R, T, V) are shown. PV cusps were immunostained for intact versican (GAGβ, green) inWT (A, E, I, Q, S) and Adamts5−/−
littermates (B, F, J, R, T). Immunolocalization of cleaved versican (anti-DPEAAE, green) from WT (C, G, K, U) and Adamts5−/− littermates (D, H, L, V). Quantiﬁcation (mean±SD) of
intact versican (GAGβ, O; * denotes Pb0.003) immunolocalization and cleaved versican (anti-DPEAAE, P; * denotes Pb0.03) was performed using Amira™ software to calculate positive
pixels from digital confocal images obtained at identical gain settings. Data was obtained from 6 pairs of Adamts5−/− andWT littermate embryos at E14.5 and E17.5. Movat pentachrome
stained sections from thePVof a P1WT (M) andAdamts5−/− (N) highlight ECM, i.e. proteoglycans, blue;ﬁbrous layer red. Sister sections fromM,Nwere stained for versican (GAGβ, green
and red-propidium iodide) inQ, R respectively. PA-pulmonary artey; RV right ventricle; An-Anterior cusp; Lt-left cusp; Rt-right cusp; S-spongiosa.White bars (A-F) denote subendocardial
compaction of mesenchyme in the WT versus Adamts5-/-. Scale bars: A, C, E, K, U=50 μm; M, Q=100 μm; G, I, S=50 μm.
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Fig. 7. Pulmonary valve cusps from Adamts5−/− mice do not exhibit BMP2 down-
regulation and restricted expression domain compared to WT littermates. Immunohisto-
chemistry of BMP2 (green) is shown in the PVofWT (A,C, C′, E) andAdamts5−/− (B,D,D′, F)
at E15.5 (A, B), E17.5 (C, C′, D, D′) and P1 (E, F). Colormaps depict positive pixels for BMP2
staining at E17.5 (C′, D′). The graph in G depicts mean fold increase above WT of positive
BMP2pixel area/valvecuspareaat E17.5 (*denotesPb0.001); n=6WT;n=6Adamts5−/−;
bars=+/− SD of the mean. Green (A, B, C, D, E, F) -BMP2; red (A, B, C, D, E, F) - propidium
iodide; An- anterior cusp of the PV; Rt- right cusp; Lt-left cusp; PA-pulmonary artery; S-
spongiosa, (versican containing) layer; P1-postnatal day 1. Scale bar A=50 μm.
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not down-regulated and restricted in the ECM of valve cusps of
Adamts5 deﬁcient mice compared to WT littermates during valvematuration (Fig. 7). At E17.5 in WT mice the BMP2 was restricted to
the spongiosa layer and the expression intensity was reduced (Fig. 7C,
C′) while in the Adamts5−/− PV there was increased intensity as well
as a lack of restriction of BMP2 (Fig. 7D, D′, *Pb0.001). The BMP2
expression differences in the Adamts5−/− PV continued until after
birth in postnatal day 1 (P1) (Figs. 7E, F). Therefore mesenchyme in
the valve cusps from ADAMTS5 deﬁcient mice has both an increased
amount of BMP2 as well as an increased domain of expression
compared to WT littermates.
Since BMP2 has been shown to increase expression of the
transcription factor Sox9, a SRY transcription factor that is highly
expressed in undifferentiated valve mesenchyme, we also examined
the expression pattern and levels of Sox9 in the ADAMTS5 null mice
(Fig. 8). Sox9 is highly expressed in endocardial mesenchyme
throughout the cushion at E12.5 in both Adamts5−/− and WT
littermates (Figs. 8A, B). At E14.5 prior to signiﬁcant stratiﬁcation of
ECM, there were slight differences in the Sox9 staining in the Adamts5
deﬁcient mice evident at the ventricular aspect of the cusps and
subjacent to the endocardium (Figs. 8C, D). Colormaps were utilized
to identify the pixel intensities of Sox9 staining in individual nuclei
to highlight the differences betweenWT and Adamts5−/− PV (Fig. 8C′,
D′, E and F). Quantiﬁcation of Sox9 staining at E17.5 when theWT has
decreased expression (Fig. 8E) compared to earlier in development,
showed signiﬁcant differences compared to Adamts5−/− (Figs. 8F, G,
*Pb0.003). These studies revealed that both the expression intensity
and domain of Sox9 were not developmentally down-regulated in the
cusps of ADAMTS5 null mice at E17.5. Sox9 expression in WT mice at
E17.5 was restricted to mesenchymal cells (Fig. 8E) in the arterial
region of the cusps while ADAMTS5 deﬁcient mice showed little or no
mesenchymal restriction of Sox9 (Fig. 8F) and were reminiscent of
valve mesenchyme earlier in development (E14.5 (Fig. 8C, C′) and
E12, A,B). Collectively these data show that loss of versican processing
by ADAMTS5 in the endocardium affects BMP2 and Sox9 expression in
underlying mesenchyme during late fetal stages of PV maturation.
Versican heterozygousity rescues the Adamts5−/− cardiac valve
morphology and BMP2/Sox9 signaling, implicating failure to cleave
versican is a primary mechanism that contributes to myxomatous valve
formation
To test the hypothesis that the clearance of versicanwas a signiﬁcant
role of ADAMTS5 in developing valves we reduced versican (Vcan) in
theAdamts5−/−miceusing theVcanhdfmutant. TheVcanhdf allelemouse
results in inactivation of the Vcan gene (Mjaatvedt et al., 1998).
Although Vcanhdf/hdf mice die during mid-gestation, the Vcan+/hdf
heterozygous mice are viable, albeit with reduced amount of versican
in the (atrioventricular) AVC (Wirrig et al., 2007), and as we have
determined, in the PV (Figs. 9A, D). When the Vcan+/hdf were interbred
with the Adamts5−/− there was signiﬁcant rescue of the PV phenotype
at E17.5 in the Adamts5−/−;Vcan+/hdf (rescue; n=11) mice (Figs. 9C,G,
K, O) when compared quantitatively with the appropriate littermate
controls Adamts5−/−; Vcan+/+ (n=11, *Pb0.003) (Figs. 9B,F,J,N),
Adamts5+/+; Vcan+/+ (n=6, *Pb0.008) (Figs. 9A,E,I,M). The AV and
MV of the Adamts5−/−;Vcan+/hdf mice also had statistically signiﬁcant
rescue of the enlarged valve phenotype compared to Adamts5−/−;
Vcan+/+ mice. While both leaﬂets of the MV at E17.5 showed
phenotypic rescue in the Adamts5−/−;Vcan+/hdf compared to
Adamts5−/−;Vcan+/+, only the left cusp of the AV showed statistically
signiﬁcant rescue, the right cusp did not (Supplemental Fig. 2). Taken
together, these data showed that versican heterozygousity signiﬁcantly
rescued the valvular anomalies in Adamts5−/− mice, but did not
completely restore normal architecture.
We hypothesized that morphological rescue of the Adamts5−/−;
Vcan+/hdf indicated that BMP2 and Sox9 expression would also be
down-regulated in the Adamts5−/−;Vcan+/hdf valves compared to
Adamts5−/−. Both BMP2 and Sox9 were down-regulated compared to
Fig. 8. In late fetal stage valves from Adamts5−/− mice Sox9 expression intensity and
domain is not decreased like WT littermates. Sox9 expression obtained by immuno-
localization is shown in the PV of WT (A, C, C′, E) and Adamts5−/− (B, D, D′, F) at E12.5
(A, B), E14.5 (C, C′, D, D′) outlined in white and E17.5 (E, F) outlined in white.
Colormaps depict pixel intensity of Sox9 staining at E14.5 (C′, D′) and E17.5 (E, F). The
graph in G shows mean positive Sox9 pixels per nuclei in PV cusps at E17.5 (* denotes
Pb0.003); n=6WT; n=6; bars=+/− SD of themean. Green (A, B, C, D)-Sox9; red (A,
B, C, D)- propidium iodide; OFT-outﬂow tract; PA-pulmonary artery; An-anterior cusp
of the PA valve; Rt-right cusp; S-spongiosa. Scale bar in A=150 μm, C=50 μm.
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expansion of the spongiosa region and versican accumulation in the
Adamts5−/− with BMP2/Sox9 expression in myxomatous valves,
suggesting that this signaling pathway contributes to myxomatous
valve formation during development.Discussion
These data show for the ﬁrst time that loss of an ECM protease
results in abnormal valve development that contributes to myxoma-
tous degeneration in the adult. Thus, these data provide a novel
example of how valve malformations during development can result
in adult valve disease. The expression of ADAMTS5 in the valvular
endocardium suggests that underlying mesenchyme is dependent on
versican proteolysis to remodel the subendocardial ECM for mesen-
chymal differentiation during valve maturation. Furthermore loss of
ADAMTS5 could not be compensated by ADAMTS1 or ADAMTS9 that
we have previously shown to be present during cardiac valve
development (Kern et al., 2006, 2010).
Our studies indicate that by late fetal development the ADAMTS5
deﬁcient mice have grossly myxomatous PV. At this time point we
hypothesize that multiple intersecting signaling pathways including
BMP2/Sox9 as well as factors considered secondary to the direct role of
ADAMTS5 contribute to the cardiac valve malformations. To begin to
elucidate the initial mechanism or underlying etiology of the myxoma-
tousphenotype in theADAMTS5deﬁcient valves our analysis focusedon
the proteoglycan substrates that are directly cleaved by ADAMTS5.
(Longpre et al., 2009; McCulloch et al., 2009b). Our data strongly
implicated versican, a critical component of the endocardial ECM
(Mjaatvedt et al., 2001; Mjaatvedt et al., 1998) that is cleaved during
murine cardiac development (Kern et al., 2006) as a critical substrate of
ADAMTS5 in developing cardiac valves. In fact we observed reduced
versican cleaved fragments in ADAMTS5 deﬁcient valve cusps, with
concomitant accumulation of intact versican, and increased histochem-
ical staining for proteoglycans. Although the ADAMTS5 protein was not
detectable at E12.5, the loss of versican cleaved fragments in the
subjacent ECM was evident in the ADAMTS5 deﬁcient endocardial
cushions. β-gal staining indicated that the Adamts5 genewas expressed
by the overlying endocardium prior to this time point. As development
progressed, intact versican accumulated in theADAMTS5deﬁcient valve
cusps, leading us to hypothesize that versican cleavage was needed for
its clearance during valve maturation. However, determining a primary
defect in theADAMTS5 deﬁcient valves is complicated by the fact that in
addition to a loss of versican cleavage fragments we observed
accumulation of the ‘intact’ substrate versican. Although the loss of
versican cleavage fragments was observed in close proximity to where
the ADAMTS5 protease was localized in the ECM, the accumulation of
versican was observed throughout the valve cusps by E17.5 greatly
augmenting and impacting valve mesenchyme that do not express or
normally require ADAMTS5 activity. To further investigate versican as a
key ADAMTS5 substrate in this context, in vivo reduction of Vcan in the
Adamts5−/− mice showed signiﬁcant restoration of normal valve
architecture and strongly suggests that versican was a deﬁnitive
substrate of ADAMTS5 in the maturing valves. However, the fact that
the ADAMTS5 valve phenotypewas not completely rescued onVcan+/hdf
background leaves open the possibility that cleaved versican fragments
as well as the lack of proteolysis of other ADAMTS5 substrates may also
play a role in valve development. Aggrecan, the other aggregating
proteoglycan and well-characterized substrate of ADAMTS5 is not
present in mammalian valves. Biglycan has been reported as an in vitro
substrate of ADAMTS5 (Melching et al., 2006) however at the time point
when the Adamts5−/− myxomatous valve phenotype is dramatic
(E17.5) there is not accumulation of biglycan in the Adamts5−/− PV.
Although ADAMTS5 is a member of the subfamily of proteases that
cleaves proteoglycans (Apte, 2004, 2009) it is conceivable that additional
unknown substrates may also play a role in the valve phenotype
observed in the ADAMTS5 deﬁcient heart valves. Collectively, these data
indicated that clearance of versican is likely a predominant mechanism
underlying the Adamts5−/−myxomatous valve phenotype.
Our morphometric data revealed that the PV cusps in ADAMTS5
deﬁcient mice were more signiﬁcantly affected than other valves.
During development the surrounding tissue of PV cusps and AV cusps
Fig. 9. Genetic reduction of versican in Adamts5−/− mice signiﬁcantly rescues the phenotype of developing pulmonary valves. Frontal sections of E17.5 hearts from the indicated
genotypes were immunostained for intact versican (GAGβ - green; propidium iodide - red; α-sarcomeric actin - blue) (A, B, C, D) or with H & E to outline their morphology (E, F, G,
H). Three-dimensional reconstructions of the PV from Adamts5+/+; Vcan+/+ (I); Adamts5−/−; Vcan+/+ (J) and Adamts5−/−; Vcan+/− mice (K) were generated using Amira™
reconstruction software to outline their shape, and obtain volume measurements of the PV at E17.5. Reconstruction volumes listed (Supplemental Table 1, also includes aortic valve
data). Sections of PV cusps of Adamts5+/+,Vcan+/+ (M); Adamts5−/−; Vcan+/+ (N) or Adamts5−/−; Vcan+/−mice (O) were H & E stained. Mesenchymal cell compaction (cells/unit
area) was measured using Amira™ software (L) and is expressed as mean±SD of the mean. * denotes a signiﬁcant difference in the compaction of the Adamts5−/−; Vcan+/− PV
compared to Adamts5−/−; Vcan+/+ mice (Pb0.003) and of Adamts5−/−; Vcan+/− PV compared to Adamts5+/+; Vcan+/+ PV (Pb0.008). BMP2 immunolocalization (P, Q, R) of the
indicated genotypes. Sox9 localization depicted in panels S, T, U. PA- pulmonary artery; RV-right ventricle; Rt-right cusp of the PV; An-anterior cusp of the PV; Lt-left cusp of the PV.
Scale bars: A=150 μm, E, P, S=100 μm; I=200 μm; M=30 μm.
161L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164is signiﬁcantly different. The PV cusps mature surrounded by a
transient myocardial cuff, a subset of myocardium during fetal stages
that we have shown exhibits the strongest expression of ADAMTS5 in
the heart. Therefore the morphological differences of the valve cusp
phenotype in the ADAMTS5 deﬁcient mice may be due to a
dependence of the surrounding myocardial ADAMTS5 expression, a
hypothesis that will require further experimentation. In addition,
previous reports show differential activation of VICs in the PV
compared to the AV (Aikawa et al., 2006; Merryman et al., 2007)
suggesting differences in genetic proﬁles may contribute to thedifferential phenotype observed in the maturing cusps of ADAMTS5
deﬁcient embryos. Since changes in ECM are often induced by altered
mechanical strain, differences in underlying genetic programs among
the cardiac valves cannot be viewed in isolation of the differences in
biomechanical forces. In fact, transplant studies have shown that
lower pressure in the PV compared to the AV produces thicker AV in
humans irrespective of the origin of the valve tissue (Rabkin-Aikawa
et al., 2004).
The increased mesenchymal cell proliferation in the ADAMTS5
deﬁcient mice is highly relevant to the pathology of myxomatous
162 L.E. Dupuis et al. / Developmental Biology 357 (2011) 152–164valve degeneration (Akhtar et al., 1999; Aupperle et al., 2009; Gupta et
al., 2009a; Morales et al., 1992) since activation of VIC (Aikawa et al.,
2007; Hinton et al., 2008; Rabkin-Aikawa et al.) is prevalent in
myxomatous valves of patients and mouse models of disease.
Additional reports demonstrate that a versican-rich ECM promotes
mesenchymal cell proliferation (Shepard et al., 2007; Shibata et al.,
2003; Snow et al., 2005). Versican accumulation is also associated
with intimal hyperplasia where vascular smooth muscle cells (VSMC)
proliferate (Wight, 2008); conversely, as the intimal lesion regresses,
versican is cleaved concomitant with quiescence of VSMC (Kenagy et
al., 2005, 2006). A loss of intact versican due to over-expression of
ADAMTS1 in the developing myocardium results in a lack of
myocardial growth (Stankunas et al., 2008). However, the increase
in ADAMTS1 also results in an over-production of versican fragments
(Stankunas et al., 2008) that may have alternative bioactivity and
suppress proliferation of cardiomyocytes. The fact that ADAMTS5 is
more readily detected on the ventricular face and hinge regions of the
SLV cusps may indicate that versican proteolysis is required in the
specialized ECM of cardiac valves that is subjected to severe tension or
shear stress. The aorta, a tissue that withstands severe biomechanical
force, exhibits expression of multiple ADAMTS proteases (Jonsson-
Rylander et al., 2005; Kenagy et al., 2005; Sandy, 2001; Sandy et al.,
2001) and is where versican proteolysis was initially discovered
(Sandy, 2001; Sandy et al., 2001). In fact, differential blood ﬂow
increases activity of ADAMTS proteases and versican cleavage in the
descending aorta (Kenagy et al., 2005, 2009). These data may also
indicate a role for versican proteolysis in elastogenesis either directly
in elastin ﬁber assembly or indirectly in distribution of other ﬁbrous
matrix components and growth factor sequestration. We hypothesize
that ADAMTS5 proteolysis of versican is essential for ﬁbrous ECM
formation and elastogenesis in the ventricular aspect of the semi-
lunar valves to provide appropriate strength and stretch for mature
cardiac valves. Further investigation will be required to determine a
role if any, for versican cleaved fragments in the maturation of the
cardiovascular ECM.
ADAMTS5 represents one of the few endocardially-expressed
genes that inﬂuence underlying mesenchyme during valve matura-
tion. Initially the loss of versican cleavage at E12.5 resulted in a
decrease in mesenchymal compaction subjacent to the endocardium.
How the developing valves sense the increased shear stress of blood
ﬂow in the growing fetus and respond in the form of ECM
production is a critical and unresolved question, but there is an
emerging role for the transcription factor NFATc1 (Combs and
Yutzey, 2009; de la Pompa et al., 1998; Jang et al., 2010; Ranger et
al., 1998). We hypothesize that subendocardial ECM remodeling by
ADAMTS5 may in turn promote HB-EGF signaling and dysregulation
results in an increase in mesenchymal cell proliferation and lack of
BMP down-regulation (Jackson et al., 2003). Increased BMP2 also
correlates with hyperplastic valves in other mouse models (Clark et
al., 1999; Delot, 2003; Delot et al., 2003; Kim et al., 2001; Shelton
and Yutzey, 2007). BMP2 activates Sox9, a SRY-related transcription
factor (Akiyama et al., 2002),(Lincoln et al., 2006) and studies by
Lincoln et. al, (Peacock et al., 2010) show that loss of Sox9 in
developing cardiac valves correlates with decreased proteoglycan
staining which is consistent with ﬁndings presented here. These data
suggest that Sox9 is critical for maintaining a proteoglycan
compartment, i.e. the spongiosa. Here we demonstrated that BMP2
and Sox9 were restricted to the spongiosa in normal valves by late
fetal development but in the ADAMTS5 deﬁcient mice BMP2 and
Sox9 were expressed throughout the valve mesenchyme. To date
membrane receptors that directly bind versican have not been
identiﬁed although it has been extensively investigated. However,
persistence of a proteoglycan-rich ECM has been shown to facilitate
growth factor binding, prevent growth factor degradation as well as
stabilize growth factor receptor interactions (Kantola et al., 2008;
Lee et al., 2006).In addition, versican binds to other matrix components
including hyaluronan (N-terminal domain), ﬁbronectin and ﬁbu-
lin-1 (C-terminus domain) (Ohno-Jinno et al., 2008), therefore we
speculate that changes in versican proteolysis may mediate
changes in growth factor signaling and binding through its ECM
binding partners. Furthermore, it is likely that other substrates of
ADAMTS5 have not been elucidated in the context of valve
maturation. How additional i.e. yet to be discovered, ADAMTS5
substrates may affect other intersecting signaling pathways and/or
augment the changes in BMP2/Sox9 that we have observed in the
ADAMTS5 deﬁcient valves remains to be investigated. Our ongoing
investigation into the role of ECM remodeling in valve develop-
ment has brought to the forefront challenges in terminology when
referring to primary and secondary defects that contribute to the
myxomatous valve phenotype of the ADAMTS5 deﬁcient mice.
Analysis of the ADAMTS5 deﬁcient valves has revealed changes in
versican cleavage fragment levels, accumulation of the ‘intact’
substrate, and strongly suggests that other ECM proteins that
directly bind versican may also be altered in the ADAMTS5 valve
cusps. In addition versican directly affects growth factor binding
sequestration in the ECM. At what point is the accumulation of the
ADAMTS5 substrate versican considered a primary defect in the
context of ECM remodeling? Data outlined here suggests that
further investigation will be required to determine which factors
are primary or secondary and to what extent versican binding ECM
partners contribute to the phenotype and their temporal role in
progression of valve phenotype in the ADAMTS5 deﬁcient mouse
model. Our approach here was to deﬁne the initial observable
defects in the ADAMTS5 deﬁcient mice that were in close
proximity to ADAMTS5 expression, and correlated with known
ADAMTS5 ECM substrates. Progression of these subtle malforma-
tions was followed to late fetal development where there was a
dramatic myxomatous valve phenotype. This work also suggests
that analysis of the entire ECM proteomic proﬁle during normal
development and in disease may be required to understand how
ECM remodeling events impact not only ECM organization but also
cell behavior, cell signaling and cross-talk of pathway components
during valve development and disease states.
The studies and genetic models used here to experimentally alter
versican abundance and cleavage during valve maturation identify
versican as a novel modulator of endothelial–mesenchymal signaling
that is critical for cardiac valve maturation. Finally, while previous
studies have demonstrated that increased versican is a hallmark of
myxomatous valve degeneration and disease (Akhtar et al., 1999;
Aupperle et al., 2009; Gupta et al., 2009a; Morales et al., 1992), the
present work as well as published ﬁndings on ADAMTS9 (Kern et al.,
2010) suggest that the myxomatous phenotype may result from loss
of versican-degrading protease activity, including ADAMTS5. These
studies suggest that mutations affecting the expression or function of
ADAMTS5may have the potential to cause myxomatous valve disease.
The ADAMTS5 deﬁcient mice presented here will provide a viable
model with full penetrance of myxomatous degeneration that will aid
in testing future therapeutic interventions for the correction of
developmental abnormalities and adult myxomatous valve disease.
Collectively these data demonstrate for the ﬁrst time the mechanism
of versican cleavage and ADAMTS5 as important mediators of ECM
stratiﬁcation required for valve maturation in the four-chambered
heart.
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